Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
- Revenue in USD (TTM)17.20m
- Net income in USD-102.14m
- Incorporated2004
- Employees81.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.84bn | 122.00 | -- | 5.22 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.85bn | 128.00 | 49.15 | 5.80 | 43.64 | 9.01 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Syndax Pharmaceuticals Inc | 111.55m | -311.58m | 1.85bn | 270.00 | -- | 16.05 | -- | 16.61 | -3.61 | -3.61 | 1.29 | 1.33 | 0.2282 | -- | 4.67 | 413,151.80 | -63.74 | -32.19 | -77.50 | -35.11 | 95.44 | -- | -279.31 | -440.06 | 4.42 | -87.92 | 0.7487 | -- | -- | 73.25 | -52.25 | -- | -- | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 1.96bn | 291.00 | -- | 6.01 | -- | 73.19 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
| Recursion Pharmaceuticals Inc | 43.69m | -715.54m | 2.00bn | 840.00 | -- | 1.81 | -- | 45.81 | -1.81 | -1.81 | 0.109 | 2.13 | 0.0411 | -- | 3.62 | 52,010.71 | -67.31 | -42.93 | -76.86 | -48.71 | -59.01 | -- | -1,637.81 | -828.92 | -- | -- | 0.0195 | -- | 32.00 | 90.93 | -41.33 | -- | 28.49 | -- |
| Soleno Therapeutics Inc | 98.68m | -78.45m | 2.18bn | 152.00 | -- | 4.40 | -- | 22.04 | -1.84 | -1.84 | 2.02 | 9.21 | 0.2201 | -- | -- | 1,072,554.00 | -17.50 | -59.81 | -18.49 | -66.17 | 98.14 | -- | -79.50 | -- | 15.88 | -- | 0.0915 | -- | -- | -- | -351.04 | -- | 59.68 | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.18bn | 78.00 | -- | 3.99 | -- | 707.91 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Mesoblast Ltd (ADR) | 17.20m | -102.14m | 2.28bn | 81.00 | -- | 3.85 | -- | 132.68 | -0.8453 | -0.8453 | 0.1424 | 4.67 | 0.0237 | -- | 2.25 | 212,321.00 | -14.05 | -13.19 | -15.99 | -14.68 | 70.17 | -132.14 | -593.92 | -957.40 | 1.77 | -4.50 | 0.1766 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.33bn | 125.00 | -- | 6.13 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.41bn | 619.00 | -- | 10.99 | -- | 8.68 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | -- | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.46bn | 51.00 | -- | 4.26 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Wave Life Sciences Ltd | 109.23m | -121.95m | 2.48bn | 287.00 | -- | 17.49 | -- | 22.74 | -0.7363 | -0.7363 | 0.6661 | 0.8262 | 0.3642 | -- | 21.85 | 380,592.30 | -40.66 | -48.01 | -71.05 | -88.09 | -- | -- | -111.64 | -205.56 | -- | -- | 0.00 | -- | -4.42 | 46.62 | -68.67 | -- | -24.87 | -- |
| Arcus Biosciences Inc | 240.00m | -341.00m | 2.55bn | 627.00 | -- | 5.10 | -- | 10.64 | -3.43 | -3.43 | 2.38 | 4.07 | 0.2156 | -- | 13.71 | 382,775.10 | -30.64 | -16.91 | -38.40 | -19.76 | -- | -- | -142.08 | -97.85 | -- | -- | 0.1835 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.60bn | 95.00 | -- | 6.78 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.71bn | 385.00 | -- | 36.87 | -- | 6.22 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
Data as of Feb 11 2026. Currency figures normalised to Mesoblast Ltd's reporting currency: US Dollar USD
2.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Legal & General Investment Management Ltd.as of 30 Sep 2025 | 651.42k | 0.51% |
| Morgan Stanley & Co. International Plcas of 30 Sep 2025 | 413.52k | 0.32% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 407.28k | 0.32% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 376.17k | 0.29% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 271.49k | 0.21% |
| Aperio Group LLCas of 30 Sep 2025 | 137.23k | 0.11% |
| BofA Securities, Inc.as of 30 Sep 2025 | 105.09k | 0.08% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 90.83k | 0.07% |
| Penbrook Management LLCas of 31 Dec 2025 | 87.58k | 0.07% |
| Prosperity Wealth Management, Inc.as of 30 Sep 2025 | 49.95k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
